ConductScience.org, home

Comparison · NCT01499511-32241691

ASCOT Participants Amlodipine vs ASCOT Participants Atenolol: Number of Participants Who Have Developed Diabetes Since the End of the ASCOT Trial

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. ASCOT Participants Amlodipine vs ASCOT Participants Atenolol: Number of Participants Who Have Developed Diabetes Since the End of the ASCOT Trial. Trial comparisons, record NCT01499511-32241691. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01499511-32241691

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.370.3380.402wilson
Risk in group 20.3940.3610.428wilson
Risk difference, group 1 minus group 2-0.0242-0.07040.022newcombe hybrid score
Risk ratio, group 1 over group 20.9380.8311.06log
Odds ratio, group 1 over group 20.9020.7421.1log
Number needed to treat, for one fewer participant with the outcome on ASCOT Participants Amlodipine than on ASCOT Participants Atenolol41.2from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1ASCOT Participants AmlodipineIt is follow up group from the ASCOT study, after treatment with amlodipine for 5.5 years. No treatment only follow up.322871OG000
Group 2ASCOT Participants AtenololIt is follow up group from the ASCOT study, after treatment with atenolol for 5.5 years. No treatment only follow up.325825OG001

Outcome

Type
SECONDARY
Title
Number of Participants Who Have Developed Diabetes Since the End of the ASCOT Trial
Description
Diabetes morbidity after 16 years in patients recruited into the Anglo-Scandinavian Outcomes trial
Time frame
16 years
Population
22 participants had missing data

Source ClinicalTrials.gov

Trial

Title
Anglo-Scandinavian Cardiac Outcomes Trial: Post Trial Follow-Up Study
NCT number
NCT01499511
Phases
Conditions
Hypertension, Diabetes, Death From Cardiovascular Disease, Myocardial Infarction, Stroke
Interventions
Lead sponsor
Imperial College London
Results first posted
2019-12-03

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01499511-32241691